Speaker Profile
Ph.D., CEO, BioEclipse Tx
Biography
Dr. Contag has led both public (President and CEO, Xenogen Corp.,NASDAQ:XGEN), and private companies and is currently the CEO of BioEclipseTherapeutics. As CEO of BioEclipse Dr. Contag was named in the top 100 mostintriguing entrepreneurs of 2018 by Goldman Sachs and in 2020 ranked in thetop 10 of the San Francisco Bay Areas Women-Led most Funded Life ScienceCompanies. BioEclipse was also named one of the top five start-up companiesin the world tackling ovarian cancer in 2021 and 2024, and top 70 startups in SanFrancisco in 2021. In 2022, received as Principle Investigator, an $8M CIRMCLIN2 grant funding the BioEclipse phase I clinical trial. Dr. Contag was alsonamed one of the Top 25 Women in Small Business by Fortune magazine. Sheis widely published and has over 40 patents issued as inventor.
Talk
Optimally Designed Cancer Therapeutics Targeting Tumor Microenvironment
CRX100 carries a specific payload that activates the innate immune system andcauses tumor cell lysis thus influencing the tumor microenvironment by a fulsomeadaptive immune response against tumor-specific antigens, while reliablyinducing tumor cell sensitivity to checkpoint inhibitors.
Emerging Therapeutics Showcase:
BioEclipse Therapeutics
BioEclipse is a clinical stage immune-oncology company in phase 1 trials with
excellent outcomes in late stage ovarian cancer patients. BioEclipse CRX100 is
targeting resistant and refractory late stage solid tumors and can be used as a
monotherapy or in combination with pembrolizumab.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
